Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease

Clinical Nephrology

Volumn 51, Issue 1, 1999, Pages 27-33

  Weinreich, Th ^a   Zapf, J ^b   Schmidt Gayk, H ^b   Ritzel, H ^b   Delling, G ^b   Reichel, H ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Adynamic bone disease; IGF 1; IGF 2; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; OSTEOCALCIN; PARATHYROID HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; CLINICAL ARTICLE; DIALYSIS; FEMALE; HEMODIALYSIS; HISTOLOGY; HUMAN; MALE; PATHOGENESIS; PERITONEAL DIALYSIS; SECONDARY HYPERPARATHYROIDISM; SERODIAGNOSIS;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 0032928774     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Andress DL, Pandian MR, Endres DB, Kopp JB 1989 Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int 36: 471-477
2. Blind E, Schnidt-Gayk H, Armbruster FP, Stadler A 1987 Measurement of intact human parathyrin by an extracting two-site immunoradiometric assay. Clin Chem 33: 1376-1381
3. Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Pasquali M, Perruza I, Manni M, Sardella D 1991 Plasma insulin-like growth factor-1 and bone formation parameters in predialysis chronic renal failure. Miner Electrolyte Metab 17: 153-159
4. Colston KW, Perks CM, Xie SP, Holly JMP 1998 Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like groth factor binding protein-3. J Molecular Endocrinol 20: 157-162
5. Condamine L, Vztovsnik F, Friedlander G, Menaa C, Garabedian M 1994 Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells. J Clin Invest 94: 1673-1679
6. Conover CA 1992 Potentiation of insulin-like growth factor action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology 130: 3191-3199
7. Couttenye MM, D'Haese PC, Van Hoof VO et al 1996 Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant II: 1065-1072
8. D'Haese PC, Couttenye MM, De Broe ME 1996 Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 11 (Suppl 3): 74-79
9. Delling G, Dreyer Th, Hahn M, Roser K, Vogel M, Welkerling H, Wolf E 1990 Pathomorphologie metabolischer Osteopathien - Aussagemoglichkeiten an Beckenkammbiopsien, Pathophysiologie und neuere Vorstellungen zur Spongiosastruktur. Der Internist 31: 737-744
10. Fouque D, Le Bouc Y, Laville M, Combranous F, Joly MO, Raton P, Zech P 1995 Insulin-like growth factor-1 and its binding proteins during a low-protein diet in chronic renal failure. J Am Soc Nephrol 6: 1427-1433
11. Fouque D, Peng SC, Kopple JD 1995 Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int 47: 876-883
12. Fournier A, Yverneau PH, Hue P, Said S, Hamdini N, Eldin HM, Mohageb S, Orisiu R, Marie A, Cohen Solal ME, Moriniere P 1994 Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypertens 3: 396-410
13. Gerakis A, Hutchison AJ, Apostolou Th, Freemont AJ, Bilis A 1996 Biochemical markers for noninvasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 11: 2430-2438
14. Grispoon SK, Baum HBA, Peterson S, Klibanski A 1995 Effects of rh-IGF-1 administration on bone turnover during short-term fasting. J Clin Invest 96: 900-906
15. Hutchinson AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ et al 1993 Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in endstage renal failure. Kidney Int 44: 1071-1077
16. Jehle PM, Ostertag A, Schulten K, Stracke S, Jehle D, Mohan S, Keller F 1996 Bone metabolism in renal osteopathy: Relation of insulin-like growth factor-1 and IGF binding proteins to biochemical markers of bone metabolism, bone histology and corticalis. Osteologie Forum 2: 161-167
17. Klaus G, Weber L, Rodriguez J, Fernandez P, Klein T, Grulich-Henn J, Hügel U, Ritz E, Mehis O 1998 Interaction of IGF-1 and lalpha,25(OH)2D3 on receptor expression and growth stimulation in rat growth plate chondrocytes. Kidney Int 53: 1152-1161
18. Landin-Wilhelmsen K, Wilhelmsen L, Luppas G, Rosen T, Lindstedt G, Lundberg PA, Bengtsson BA 1994 Serum insulin-like growth factor 1 in a random population sample of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 41: 351-357
19. Musci I, Hercz G 1997 Adynamic bone disease: Pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 6: 356-362
20. Qi Q, Monier-Faugere M-C, Geng Z, Malluche HH 1995 Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622-631
21. Reichel H, Drueke TB, Rik E 1997 Skeletal disorders. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DNS, Rik E, Winearls CG: Oxford Textbook of Nephrology, Oxford, 1954-1981
22. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodmam WG 1994 Biochemical markers of renal osteodystrophy in pediatric patients undergging CAPD/CCPD. Kidney Int 45: 253-258
23. Schmid C 1993 IGFs: function and clinical importance 2. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med 234: 535-542
24. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenta SS, Segre GV 1993 The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 43: 436-442
25. Toenshoff B, Blum W, Wingen AM, Mehis O, European Study Group for Nutritional treatment of Chronic Renal Failure in Childhood 1995 Serum insulin-like growth factors and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: Relationship to height and glomerular filtration rate. J Clin Endocrin Metab 80: 2684-2691
26. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP et al 1995 Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a bester response to PTH. Kidney Int 47: 1434-1442
27. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS et al 1995 Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Min Res 10: 932-939
28. Zapf J, Waller H, Froesch ER 1981 Radioimmunological determination of insulin-like growth factor 1 and 2 in normal subjects and in patients with growth disorders and extra pancreatic tumor hypoglycemia. J Clin Invest 68: 1321-1330
29. Zapf J, Schmid C, Guber HP, Waldvogel M, Hauri C, Futo E, Hosenlopp P, Binoux M, Froesch ER 1990 Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased express ion of IGF binding protein 2 during IGF 1 treament of healthy adults and in patients with extrapancreatic tumor hypoglycemia. J Clin Invest 86: 952-961
30. 3 on circulating insulinlike growth factor-1 and. β-microglobulin in patients with osteoporosis. Calif Tissue Int 60: 236-239